1
Participants
Start Date
October 31, 2007
Primary Completion Date
July 31, 2009
Study Completion Date
February 28, 2010
exenatide
Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
University of California Davis Medical Center, Sacramento
Collaborators (1)
Amylin Pharmaceuticals, LLC.
INDUSTRY
Eli Lilly and Company
INDUSTRY
University of California, Davis
OTHER